Browse the evidence

Ectopic lipid accumulation (specifically diacylglycerol) in skeletal muscle and liver directly causes insulin resistance by activating specific protein kinase C (PKC) isoforms (PKCθ in muscle, PKCε in liver), which impair insulin receptor signaling.

Insulin resistance in obesity is driven by specific fat molecules (DAG) accumulating in muscle and liver, which block insulin signals. Reducing ectopic fat (via weight loss or exercise) can restore sensitivity.

Hepatic insulin resistance is characterized by a 'selective' defect where insulin fails to suppress gluconeogenesis but continues to stimulate de novo lipogenesis, driven by substrate flux (fatty acids and glucose) rather than insulin signaling alone.

In T2D, the liver ignores insulin's command to stop making glucose, but still responds to high sugar/fat intake by making more fat. Managing carbohydrate and fat intake is critical to reducing liver fat and glucose production.

Adipose tissue inflammation and macrophage infiltration cause insulin resistance by increasing lipolysis, which floods the liver with fatty acids and glycerol, driving gluconeogenesis and hyperglycemia independently of hepatic insulin signaling.

In obesity, inflamed fat tissue releases excess fatty acids and glycerol, which force the liver to produce more glucose and fat. Reducing adipose inflammation and lipolysis (via weight loss) improves liver function.

The FTO obesity-risk allele (rs1421085) promotes obesity by disrupting ARID5B binding, which derepresses IRX3/IRX5 expression in adipocyte progenitors, shifting them from energy-dissipating beige adipocytes to energy-storing white adipocytes and reducing mitochondrial thermogenesis.

This research identifies a specific genetic variant (FTO rs1421085) that causes fat cells to store more energy and burn less as heat. While you cannot change your DNA, this finding highlights a biological target (IRX3/IRX5) for future therapies. For now, standard energy balance principles apply, but this mechanism explains why some individuals may have a biological predisposition to store fat more efficiently.

Knocking down IRX3 or IRX5 in adipocytes from individuals with the FTO risk allele restores mitochondrial thermogenesis by a factor of 7, effectively reversing the obesity-associated phenotype.

This finding suggests that future drugs targeting IRX3 or IRX5 could help people with the FTO obesity gene burn more fat. It is not a current lifestyle intervention but a promising area for pharmaceutical development.

The endogenous circadian pacemaker significantly modulates sleep propensity, with sleep latency being shortest (highest propensity) when sleep coincides with the minimum of the core body temperature rhythm, and longest (lowest propensity) when it coincides with the maximum.

To fall asleep faster, try to align your bedtime with your body's natural temperature minimum, which typically occurs in the early morning hours (e.g., 4-6 AM) for most people. If you must sleep at other times, expect longer sleep latency. Consistent sleep-wake times help stabilize this rhythm.

The circadian pacemaker significantly modulates the amount of REM sleep, with maximum REM sleep occurring shortly after the minimum of the core body temperature rhythm, and minimum REM sleep occurring during the plateau phase.

If you are concerned about REM sleep deprivation, note that REM sleep is naturally higher in the early morning hours (shortly after the body temperature minimum). Disrupting this phase (e.g., by waking up too early) may disproportionately reduce REM sleep.

Slow-wave activity (SWA, 0.75-4.5 Hz) in non-REM sleep is modulated by both the circadian pacemaker and the homeostatic sleep process, with the circadian modulation peaking around the minimum of the core body temperature rhythm.

Deep sleep (SWA) is highest when you sleep during your biological night (temperature minimum). Additionally, SWA increases with the duration of prior wakefulness. To maximize deep sleep, ensure you are sleep-deprived enough (homeostatic pressure) and sleeping during your circadian night.

Adipose tissue inflammation, driven by immune cell infiltration (macrophages, T cells) and pro-inflammatory cytokines (TNFα, IL-6), is a causal factor for systemic insulin resistance in obesity.

Obesity is not just about storing energy; it triggers inflammation in fat tissue that blocks insulin action. Reducing this inflammation, potentially through weight loss or anti-inflammatory strategies, can improve insulin sensitivity.

Gastrointestinal satiation signals, specifically cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY), regulate meal termination and size through neural and hormonal pathways to the hindbrain, acting synergistically with gastric distention.

Your body uses specific gut hormones (CCK, GLP-1, PYY) to tell your brain when to stop eating. These are released in response to nutrients, especially fats and proteins, in the intestine. While these signals are crucial for normal eating, simply relying on stomach stretching (volume) is less effective than consuming nutrient-dense foods that trigger these hormonal pathways.

Metformin treatment in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) reduces hepatic glucose output primarily by inhibiting gluconeogenesis, leading to improved glycemic control and preferential loss of adipose tissue.

If you have type 2 diabetes and are overweight, metformin can help lower your blood sugar and reduce body fat without causing muscle loss. Start with a low dose to minimize stomach upset, and gradually increase it as tolerated. It works by reducing the amount of sugar your liver produces.

Metformin and thiazolidinediones improve glucose homeostasis in Type 2 Diabetes patients partly by activating AMPK.

Metformin is a common medication for Type 2 Diabetes that works, in part, by activating AMPK. This helps your body manage blood sugar and insulin sensitivity more effectively.

Adipose tissue functions as an active endocrine organ that secretes adipocytokines (e.g., TNF-α, IL-6, leptin, adiponectin) which regulate whole-body metabolism, insulin sensitivity, and inflammation, rather than serving merely as inert fat storage.

Understand that your fat tissue is an active organ that sends signals to your brain and other organs. It doesn't just store energy; it regulates your appetite, insulin sensitivity, and inflammation through hormones like leptin and adiponectin. Managing fat mass is therefore managing a complex hormonal system, not just caloric storage.

Obesity induces a state of chronic low-grade inflammation in adipose tissue, primarily driven by macrophage infiltration and the secretion of pro-inflammatory cytokines (TNF-α, IL-6), which directly impairs insulin signaling and contributes to insulin resistance.

Excess body fat, particularly visceral fat, triggers an inflammatory response involving immune cells (macrophages) that release hormones like TNF-α and IL-6. These hormones interfere with insulin signaling, leading to insulin resistance. Reducing visceral fat can help lower this inflammation and improve metabolic health.

Adiponectin is an adipokine secreted exclusively by adipose tissue that improves insulin sensitivity and fatty acid oxidation, with levels inversely correlated to fat mass, making its reduction in obesity a key factor in metabolic dysfunction.

Adiponectin is a hormone made only by fat cells that helps your body use insulin and burn fatty acids. People with more body fat typically have lower levels of adiponectin, which contributes to insulin resistance. Maintaining a healthy weight helps preserve these beneficial hormone levels.

Hyperinsulinemia and elevated Insulin-like Growth Factor-I (IGF-I) levels, driven by obesity and insulin resistance, promote cancer cell growth, proliferation, and metastasis.

Managing insulin sensitivity through diet and exercise is crucial for cancer prevention, as high insulin and IGF-I levels directly fuel tumor growth and spread.

Muscle atrophy in catabolic conditions (cancer, diabetes, inactivity) is driven by the upregulation of 'atrogines' like MuRF1 and Atrogin-1, which target structural proteins for degradation via the ubiquitin-proteasome system.

Muscle loss during illness or inactivity is not just 'passive'; your body actively activates specific genes (like MuRF1 and Atrogin-1) to break down muscle protein. This process is driven by stress hormones and inflammation. Preventing or reversing this requires addressing the underlying catabolic drivers, not just 'resting'.

Transcriptional regulation by nuclear receptors (specifically PPARs, LXRs, and SREBPs) and transcription factors (ChREBP, FOXOs) serves as the primary long-term mechanism for maintaining metabolic homeostasis by coordinating glucose, lipid, and amino acid metabolism in response to fasting and feeding cycles.

Your body doesn't just burn calories; it actively reprograms its genes based on your diet to manage energy. High glucose and insulin trigger genes for fat storage (via SREBP-1c and ChREBP), while fasting and glucagon trigger genes for fat burning and glucose production (via PPARs and FOXOs). Understanding this helps explain why extreme diets can alter metabolic efficiency long-term.

IGF-I enhances the differentiated function of mature osteoblasts and stimulates bone formation, but it does not directly direct the differentiation of undifferentiated stromal cells into osteoblasts.

IGF-I supports the activity of existing bone-building cells (osteoblasts) rather than creating new ones from scratch. Maintaining healthy hormone levels supports this function.

In nondiabetic obese individuals, insulin resistance is less prevalent (26%) than insulin hypersecretion (38%), and the severity of insulin resistance is significantly lower when normalized to fat-free mass rather than total body weight.

If you are obese but have normal blood sugar, you likely do not have severe insulin resistance. Your body is likely producing high amounts of insulin (hypersecretion) to keep your blood sugar normal. This is a different metabolic state than being 'insulin resistant,' and it may respond differently to diet and lifestyle changes. Focus on reducing the demand for insulin rather than assuming your metabolism is permanently broken.

Men have a higher prevalence of type 2 diabetes than women, particularly in middle-aged populations, due to greater visceral adiposity, ectopic fat accumulation, and lower insulin sensitivity.

Men are biologically more susceptible to type 2 diabetes than women, especially between ages 35 and 69. This is largely due to storing fat around the organs (visceral fat) rather than under the skin. Men should prioritize regular screening for blood sugar and insulin resistance, as their bodies are less forgiving of poor metabolic health than women's.

The metabolic effects of IL-6 on glucose uptake and fatty acid oxidation in skeletal muscle are mediated by the activation of AMP-activated protein kinase (AMPK), as evidenced by the abrogation of these effects in cells with dominant-negative AMPK.

AMPK activation is a key pathway through which exercise-induced signals improve metabolism. Strategies that activate AMPK (like exercise itself) leverage this pathway to enhance glucose and fat handling.

Type 2 deiodinase (D2) and Type 3 deiodinase (D3) locally regulate thyroid hormone signaling within specific tissues independently of serum thyroid hormone concentrations.

Understanding that thyroid hormone action is locally controlled explains why standard blood tests might not reflect how you feel. Tissues like the brain, heart, and fat have their own local enzymes (D2 and D3) that activate or deactivate thyroid hormone. This means systemic blood levels are not the only factor determining metabolic rate or energy expenditure at the cellular level.

Depression and inflammation form a bidirectional, self-reinforcing loop where depression primes exaggerated inflammatory responses to stressors, and inflammation promotes depressive symptoms via sickness behaviors and neurobiological changes.

Managing stress, sleep, and diet is not just about physical health; it directly impacts your mental health by lowering inflammation. If you have depression, addressing lifestyle factors that drive inflammation (like obesity or poor sleep) may break the cycle of worsening mood.